Debora Nagy
Psychiatric/Mental Health · Irvine, CANPI 1962093229
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.9% of the total across 333 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 24 manufacturers, the largest accounting for just 18.9% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $4,651 and has fallen 99.1% since, to $41 in 2024. Among psychiatric/mental health clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 333 payments — averaging $21.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Johnson & Johnson$1K
- Teva Pharmaceuticals USA, Inc.$948
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$628
- Otsuka America Pharmaceutical, Inc.$610
- Sunovion Pharmaceuticals Inc.$351
- plus $2K from 18 others
What the payments were for
- Food & beverage$7,113100%
- Education$50%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 65 | $1,342 |
| Johnson & Johnson | 47 | $1,061 |
| Teva Pharmaceuticals USA, Inc. | 50 | $948 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 31 | $628 |
| Otsuka America Pharmaceutical, Inc. | 27 | $610 |
| Sunovion Pharmaceuticals Inc. | 19 | $351 |
| Alkermes, Inc. | 13 | $351 |
| Neurocrine Biosciences, Inc. | 8 | $309 |
| Avanir Pharmaceuticals, Inc. | 13 | $283 |
| Acadia Pharmaceuticals Inc | 11 | $258 |
| Lundbeck LLC | 9 | $154 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $127 |
| Adlon Therapeutics L.p. | 5 | $95 |
| Supernus Pharmaceuticals, Inc. | 4 | $86 |
| Noven Therapeutics, LLC | 4 | $85 |
| Biogen | 3 | $74 |
| Merck | 4 | $67 |
| Vanda Pharmaceuticals Inc. | 2 | $55 |
| Bausch Health US, LLC | 3 | $54 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $48 |
| Eisai Inc. | 3 | $47 |
| Almatica Pharma LLC | 2 | $41 |
| Sun Pharmaceutical Industries Inc. | 1 | $23 |
| Alfasigma USA, Inc. | 1 | $21 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ARISTADA$500
- AUSTEDO$241
- ARISTADA INITIO$125
- ABILIFY MAINTENA$121
- INGREZZA$121
- REXULTI$115
How this compares
$7,118 in reported general payments places this provider in the 95th percentile of 2,433 psychiatric/mental health providers in California.
Other psychiatric/mental health in Irvine
- Phuong TranIrvine$27K
- Dylan GuineyIrvine$25K
- Jada AlstonIrvine$18K
- Maria AcevedoIrvine$15K
- Salina LumIrvine$15K
- Sylvia GuthrieIrvine$14K
- Farhad NikooIrvine$14K
- Kelly EguchiIrvine$12K
- Michelle NguyenIrvine$11K
- Carey MartinMillbrae$745K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.